NCT07181785View on ClinicalTrials.gov

Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.

CompletedOBSERVATIONAL
Enrollment

555

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

July 12, 2023

Study Completion Date

July 12, 2023

Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
COMBINATION_PRODUCT

Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy

Anthracycline-based combinations followed or not by involved-field radiotherapy

Trial Locations (1)

Unknown

IRCCS San Raffaele Hospital, Milan

All Listed Sponsors
lead

Andrés José Maria Ferreri

OTHER